COMPANY PROFILE

IntegenX

Explore full profile

Designs, manufactures and markets automation systems facilitating reliable micro sample preparation and analysis

Pleasanton, United StatesFounded 2006Biotech & Life Sciences

Valuation $100–250M Last recorded · 2011

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About IntegenX

IntegenX specializes in providing advanced DNA analysis solutions designed for rapid human identification in forensic and clinical applications. The company serves law enforcement agencies, forensic laboratories, and healthcare providers, operating within the biotechnology and life sciences market. IntegenX's business model revolves around the development and sale of automated DNA identification systems, which significantly reduce the time required for DNA analysis from days to hours. Revenue is generated through the sale of these systems, as well as ongoing service and maintenance contracts. The company leverages cutting-edge technology to offer reliable and efficient solutions, enhancing the capabilities of its clients in solving crimes and improving patient care.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2006
Headquarters: Pleasanton, United States
Employees: 20
Open positions: None listed
Dealroom signal: 73.6/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Analytics, Biotechnology, DNA, Genetics and genomics, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest Feb 2011
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Mar 2018	$0	—	Thermo Fisher Scientific	—
DEBTDebt	Sep 2014	$10M	—	Horizon Technology Finance Corporation	—

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

IntegenX website traffic

Latest recorded traffic for IntegenX is 100 monthly website visits. IntegenX's team declined 25.9% over the past year.

Latest monthly visits100 1-year team growth-25.9%

Monthly website visitsApr 2016–May 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DGDeep GenomicsDeep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies	Toronto, Canada	Operational	112	$237M	$720M
OPOpGenMicrobial Genetic Analysis - OpGenOpGen	Gaithersburg, United States	Operational
BGBoreal GenomicsBoreal Genomics - circulating tumor DNA analysis	Los Altos, United States	Operational
GEGeospizaSoftware developer of Next Gen Sequencing DNA Genetic Analysis and LIMS	Seattle, United States	Acquired
INInivataClinical cancer genomics company harnessing the emerging potential of circulating DNA analysis	Morrisville, United States	Acquired
TOToolGenToolGen, a biotechnology company, focuses on the development of genome editing technology	Seoul, South Korea	Acquired
CGCofactor GenomicsCofactor Genomics uses RNA to diagnose disease	San Francisco, United States	Operational
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational